Please assess the completion status of the following clinical trial:

Trial Title: Nutraceutical in Cardiovascular Primary Prevention

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Age ≥18 years; Ability to provide informed written consent and to participate in the 16 weeks follow-up period And one of the following criteria~* Cardiovascular risk (SCORE) \<1% and LDL levels ≥ 190 mg/dl (confirmed after a 4-week period of life style changes)~* Cardiovascular risk (SCORE) 1% to \<5% and LDL levels ≥ 100 mg/dl (confirmed after a 4- week period of life style changes)~Exclusion Criteria:~Chronic liver disease Renal disease (creatinine clearance \<60 mg/dl) Intolerance to nutraceutical compounds Thyroid disease Alcohol consumption \>40 g/die Treatment with lipid lowering products in the previous 4 weeks Known coronary artery disease (CAD) or cerebrovascular disease Cardiovascular risk (SCORE) ≥5%

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- nutraceutical (Type: EXPERIMENTAL): after 4 weeks of lifestyle advice and changes, all subjects will receive for 8 weeks the administration of CARDIOVIS COLESTEROLO 3 mg, a nutraceutical compound containing containing red rice fermented with Monascus purpureus titrated with 3% monacolin K, hydrol mixture of olive fruit titrated with vitamin E, Coenzyme Q10 and polymethoxyflavones

Based on this trial design, predict the completion outcome and termination type (if applicable).